Product image of Levonorgestrel/Ethinylestradiol Sandoz (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Levonorgestrel/Ethinylestradiol Sandoz

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Levonorgestrel/Ethinylestradiol Sandoz (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Levonorgestrel/Ethinylestradiol Sandoz, is a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH India supplies Levonorgestrel/Ethinylestradiol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sandoz B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levonorgestrel/Ethinylestradiol is a combined estrogen‑progestogen oral contraceptive used in the hormonal birth‑control pathway.

  • Prevention of pregnancy: provides reliable hormonal contraception for women of childbearing age.
  • Menstrual cycle regulation: helps achieve more predictable and regular periods.
  • Acne management: may improve moderate acne associated with hormonal fluctuations.

How It Works

  • Levonorgestrel/Ethinylestradiol combines an estrogen (ethinylestradiol) and a progestogen (levonorgestrel) that bind to estrogen and progesterone receptors. The estrogen suppresses follicle‑stimulating hormone, while the progestogen inhibits luteinizing hormone surge, preventing ovulation. The progestogen also thickens cervical mucus and alters the endometrial lining, creating an environment unfavorable for implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: temporary swelling or discomfort.
  • Headache: occasional mild to moderate pain.
  • Weight gain: slight increase due to fluid retention.
  • Mood changes: irritability or emotional fluctuations.
  • Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in veins.
  • Pulmonary embolism: clot traveling to lungs.
  • Stroke: interruption of cerebral blood flow.
  • Myocardial infarction: heart attack risk.
  • Severe allergic reaction: rash, swelling, difficulty breathing.
  • Liver tumor: rare benign growths in the liver.

Precautions & Warnings

Before prescribing Levonorgestrel/Ethinylestradiol, clinicians should consider several safety factors.

  • Assess thrombotic risk: avoid use in women with history of clotting disorders.
  • Screen for hypertension: uncontrolled high blood pressure increases cardiovascular risk.
  • Avoid smoking: especially in women over 35 years of age.
  • Evaluate liver function: hepatic impairment may alter drug metabolism.
  • Pregnancy contraindication: do not start in women who are pregnant or suspect pregnancy.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Levonorgestrel/Ethinylestradiol may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy.
  • Rifampin and other rifamycins: decrease hormone levels, increasing pregnancy risk.
  • St. John's wort: herbal inducer that lowers plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Certain antibiotics (e.g., tetracycline, metronidazole): may slightly reduce effectiveness.
  • Antifungal agents (e.g., fluconazole): can increase hormone levels, raising side‑effect potential.
  • Protease inhibitor antiretrovirals: may require closer monitoring of contraceptive reliability.

Frequently Asked Questions

Levonorgestrel/Ethinylestradiol Sandoz is a combined estrogen‑progestogen oral tablet prescribed to prevent pregnancy in women of reproductive age. It works as a hormonal contraceptive by inhibiting ovulation and creating conditions that reduce the chance of fertilization and implantation.

The product contains ethinylestradiol (an estrogen) and levonorgestrel (a progestogen). Together they suppress the release of follicle‑stimulating and luteinizing hormones, preventing ovulation. Levonorgestrel also thickens cervical mucus and alters the uterine lining, making it less suitable for implantation.

The dosing regimen is determined by the prescribing clinician based on the specific product formulation and patient factors. Healthcare providers select the appropriate tablet strength and schedule, typically following a 21‑day active‑pill course with a 7‑day placebo interval.

No. The medication is classified as Pregnancy Category X, meaning it must not be used by women who are pregnant or suspect pregnancy. It is also generally not recommended during breastfeeding because hormonal exposure may affect milk production and infant exposure.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levonorgestrel/Ethinylestradiol combines a widely used estrogen and a second‑generation progestogen, offering a balance of efficacy and tolerability. Compared with newer formulations that may contain different progestogens, it has a well‑established safety profile but shares similar contraindications and side‑effect risks.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

The medication is taken orally, usually once daily at the same time each day, as directed by the prescriber. A typical cycle includes 21 active tablets followed by a 7‑day pill‑free interval, during which withdrawal bleeding occurs.

Serious risks include venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), arterial events such as stroke or myocardial infarction, severe allergic reactions, and rare liver tumors. Patients should be monitored for signs of these conditions and advised to seek immediate medical attention if they occur.

Women with a known history of thromboembolic disorders, uncontrolled hypertension, active liver disease, breast cancer, or those who are pregnant or breastfeeding should avoid this medication. Smoking women over 35 years of age are also advised not to use combined oral contraceptives.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT